Maternal Health News
-
Medis Strain algorithms integrated in FetalHQ
MedisStrain Algorithms Integrated infetalHQ Our Strain algorithms are integrated in thefetalHQ imaging tool which is available on Voluson™ Expert 22 from GE Healthcare.fetalHQ allows users to make an easy and comprehensive evaluation of the size, shape, and contractility of the fetal heart to make more informed decisions about maternal/ fetal well-being and delivery planning using ...
-
Daily Inspiration: Meet Gillian Henker
Today we’d like to introduce you to Gillian Henker. Hi Gillian, we’re thrilled to have a chance to learn your story today. So, before we get into specifics, maybe you can briefly walk us through how you got to where you are today. In 2014, Gillian Henker co-founded Sisu Global, leading the company’s products and technical strategy. Henker is the primary inventor of Hemafuse ...
-
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2022-- Alnylam ...
-
How BioVigil Reduces Staff Absenteeism in Hospitals
Staff absences are a problem for any employer, but are particularly challenging in hospitals and other healthcare settings. Unplanned staff absences can leave supervisors struggling to fill shifts and overwork employees who have to cover for their peers. These drops in productivity or gaps in care can put patients at risk. To combat employee absenteeism and its effects, hospitals need to ...
By BioVigil
-
BillionToOne Launches Novel Fetal Antigen NIPT as Part of UNITY Screen
BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to UNITY Screen. For pregnant patients who are alloimmunized with C, c, D, E, Duffy (Fya), or Kell (K) red blood cell (RBC) antibodies, this novel NIPT ...
-
Sydney MedTech Baymatob completes capital raise to advance life-saving labour monitoring device
Sydney medical device company Baymatob has completed a placement of $4.215 million, with proceeds used to continue in-human clinical trials for its AI-guided labour monitoring device, Oli. Cornerstoned by Australian Unity’s Future of Healthcare Fund, the placement was strongly supported by Australian institutional and high net worth investors, securing long-term capital partners to support ...
-
Santa Barbara Cottage Hospital Enhances Maternal and Fetal Safety with Go-Live of PeriGen’s PeriWatch Vigilance
PeriGen®, an innovator in perinatal early warning systems, today announced that Santa Barbara Cottage Hospital, a 519-bed acute care teaching hospital and trauma center that is part of the not-for-profit Cottage Health system, is now using PeriGen’s PeriWatch Vigilance® automated maternal-fetal early warning system (EWS) in its labor and delivery (L&D) department. Founded in ...
-
Proximie Partners with Jhpiego in New Initiative to Improve Obstetric Surgical Care
Proximie has teamed up with Jhpiego, a Johns Hopkins University affiliate, on a safe surgery project in Kenya to layer in their unique software that allows physicians anywhere in the world to virtually "scrub-in" and mentor colleagues in real time. Proximie has offered its technology to Jhpiego, a global health non-profit working in 40-plus countries, to improve obstetric surgical care for ...
-
PeriGen Deploys Mobile Version of PeriWatch Vigilance to Further Protect Moms and Babies During Childbirth
PeriGen Inc., the market leader in applying artificial intelligence (AI) to improve safety in childbirth, today introduced PeriWatch Vigilance® Mobile, a full-function browser-based solution providing access to its early warning system (EWS) and clinical decision support tool. By providing remote access to the full range of conditions monitored by PeriWatch Vigilance, the new solution ...
-
Optina Diagnostics Closes an Oversubscribed Series-A Round of CA$24.8 million
2021 Optina, an innovative diagnostics company leading the field of Retinal Imaging, Brain Health and Systemic Diseases Diagnostics, announced today the closing of an CA$24.8 million Series A round of funding. Optina’s Retinal Deep Phenotyping™ platform obtained FDA Breakthrough Device Designation status in 2019 for its non-invasive and more accessible test to improve diagnosis ...
-
SCL Health to Deploy System-Wide OB Hub Powered by PeriWatch Command Center
PeriGen Inc., the market leader in applying artificial intelligence (AI) to improve safety in childbirth, today announced that SCL Health, a health system operating eight hospitals and 150 clinics in Colorado and Montana, is launching a centralized SCL Health OB Hub utilizing PeriGen’s PeriWatch Command Center enterprise-wide telehealth-platform. Through the OB Hub, a dedicated team of ...
-
Baymatob Builds Executive Team for Next-Stage Milestones and Growth
Baymatob™, a pioneer in women’s health and AI-guided monitoring for maternity and child birth, is excited to announce the appointment of Dr Sarah McDonald as Chair of the Board, Tara Croft as Chief Executive Officer, and Tony Barclay as Acting Chief Financial Officer. Sarah is the founder of Baymatob and as CEO has worked to establish and grow the company over the last eight years. ...
-
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties
Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (rCDI) Only gut microbiome research program with five clinical studies demonstrating consistent ...
-
Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021
Analysis of data from five RBX2660 prospective studies is one of only four abstracts to receive the coveted IDWeek 2021 Program Committee Choice award for outstanding scientific research. Ferring and Rebiotix will present new data showing an association between clinical outcomes and restoration of the microbiome Research from the Phase 3 PUNCH CD3 trial on the effects of RBX2660 on deadly ...
-
MindChild Medical, Inc. Announces Gates Funded UNC LABOR Study Enrolls 6,000th Subject Recorded with Meridian™ Fetal ECG Research Device
The Meridian Fetal Research Device Accurately Extracts Fetal ECG to Enable Analytics on Fetal ECG Morphology, Heart Rate, Heart Rate Variability and Uterine Activity Using Surface Electrodes (North Andover, Massachusetts), Mindchild Medical, Inc. announced that the LABOR study recorded its 6,000th subject with MindChild’s Meridian Fetal Research Device. Jay Ward, MindChild Medical’s ...
-
US FDA awards Breakthrough Device Designation to Australian labour monitoring device, Oli
BaymatobTM, a MedTech company founded by a Sydney mother after her own traumatic birth experience, has developed a world-first labour monitoring device that has achieved US Food and Drug Administration (FDA) Breakthrough Device Designation. This sets Baymatob’s game changing maternal diagnostic tool called OliTM on an streamlined and supported path toward regulatory approval. Oli seeks to ...
-
Frontier Biotechnologies` First Long-acting Injectable (Aikening(R), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients
The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies TALENT is the world's first phase III clinical trial of the new long-acting HIV-1 fusion inhibitor, Aikening® (generic name: Albuvirtide [ABT]) in an all-Asian population TALENT ...
-
Texas Children’s Pavilion for Women Teams up With PeriGen to Bring PeriWatch Vigilance® to Malawi
Texas Children’s Pavilion for Women® announced today the launch of the PeriWatch Vigilance® program in Lilongwe, Malawi (in southern Africa), in partnership with PeriGen Advanced Perinatal Software, a provider of innovative software solutions for over 20 years with a mission to protect mothers and babies everywhere. In a public-private partnership with the Texas Children’s ...
-
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is the first microbiota-based live biotherapeutic to demonstrate efficacy as early as first recurrence of Clostridioides difficile (C. difficile) infection RBX2660 Phase 3 data add to the world’s largest and most robust clinical program ever conducted in ...
-
Asia Wipes Summit 2021
BEIJING, CHINA (April 20,2021) -" Green Innovation and Sustainable Solutions" was the key theme of the first edition of Asia Wipes Summit held in Shanghai, China April 1 -2,2021. The leading conference jointly organized by China Nonwovens & Industrial Textiles Association (CNITA) and E.J. Krause & Associates, Inc. (EJK) in the wipes industry brought together 350 participants from the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you